Ophthalmology

Papers
(The H4-Index of Ophthalmology is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045718
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data428
International Classification of Retinopathy of Prematurity, Third Edition283
Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients277
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration237
HAWK and HARRIER210
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab200
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab194
Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study164
Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19 Patients156
Primary Open-Angle Glaucoma Preferred Practice Pattern®153
Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration149
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration145
Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom129
Multifocal and Extended Depth-of-Focus Intraocular Lenses in 2020119
Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic112
Update on Intraocular Lens Power Calculation Study Protocols107
Polypoidal Choroidal Vasculopathy101
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration100
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis99
Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration97
The Risks and Benefits of Myopia Control96
Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma94
Application of Automated Quantification of Fluid Volumes to Anti–VEGF Therapy of Neovascular Age-Related Macular Degeneration92
Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease89
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)89
Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children89
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset85
Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout82
Evaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-1981
Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure80
COVID-19 Quarantine Reveals That Behavioral Changes Have an Effect on Myopia Progression78
Ganglion Cell Complex Thickness and Macular Vessel Density Loss in Primary Open-Angle Glaucoma75
Prevalence of Keratoconus Based on Scheimpflug Imaging72
Descemet Membrane Endothelial Keratoplasty versus Ultrathin Descemet Stripping Automated Endothelial Keratoplasty72
Intraocular Lens Power Formulas, Biometry, and Intraoperative Aberrometry71
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration70
Intraocular Lens Implantation in the Absence of Zonular Support: An Outcomes and Safety Update69
Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 269
Nonexudative Macular Neovascularization Supporting Outer Retina in Age-Related Macular Degeneration66
Academic Ophthalmology during and after the COVID-19 Pandemic65
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment65
Primary Retinal Detachment Outcomes Study Report Number 264
Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning63
Randomized Clinical Trial Comparing Femtosecond LASIK and Small-Incision Lenticule Extraction62
Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)61
Evolution of the Prevalence of Myopia among Taiwanese Schoolchildren61
Trends in Glaucoma Surgeries Performed by Glaucoma Subspecialists versus Nonsubspecialists on Medicare Beneficiaries from 2008 through 201661
The Association between Vision Impairment and Incidence of Dementia and Cognitive Impairment60
Comparison of Myopic Progression before, during, and after COVID-19 Lockdown59
Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children57
Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children55
Socioeconomic and Demographic Disparities in the Use of Telemedicine for Ophthalmic Care during the COVID-19 Pandemic55
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy54
0.1239218711853